|
|
Volumn 334, Issue 22, 1996, Pages 1470-1471
|
|
Chronic viral hepatitis - Benefits of current therapies
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIVIRUS AGENT;
FAMCICLOVIR;
LAMIVUDINE;
NUCLEOSIDE ANALOG;
RECOMBINANT ALPHA INTERFERON;
RIBAVIRIN;
VIRUS RNA;
ANIMAL MODEL;
CHRONIC HEPATITIS;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
EDITORIAL;
HEPATITIS B;
HEPATITIS B VIRUS;
HEPATITIS C;
HEPATITIS C VIRUS;
HUMAN;
MAJOR CLINICAL STUDY;
META ANALYSIS;
MULTICENTER STUDY;
NONHUMAN;
ORAL DRUG ADMINISTRATION;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
TREATMENT OUTCOME;
VIRUS HEPATITIS;
DNA, VIRAL;
HEPATITIS B;
HEPATITIS B E ANTIGENS;
HEPATITIS B VIRUS;
HEPATITIS, CHRONIC;
HUMANS;
INTERFERON ALFA-2B;
|
|
EID: 0029890254
PISSN: 00284793
EISSN: None
Source Type: Journal
DOI: 10.1056/NEJM199605303342210 Document Type: Editorial |
|
Times cited : (48)
|
|
References (0)
|
